Stevens Capital Management LP acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 81,819 shares of the pharmaceutical company’s stock, valued at approximately $12,440,000.

Several other institutional investors and hedge funds also recently modified their holdings of VRTX. Dimensional Fund Advisors LP lifted its stake in shares of Vertex Pharmaceuticals by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 272,933 shares of the pharmaceutical company’s stock worth $29,842,000 after purchasing an additional 5,496 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $4,387,000. Nuveen Asset Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.8% during the first quarter. Nuveen Asset Management LLC now owns 66,780 shares of the pharmaceutical company’s stock worth $7,302,000 after purchasing an additional 10,093 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $619,000. Finally, Koshinski Asset Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the second quarter worth about $220,000. Institutional investors own 93.06% of the company’s stock.

In other Vertex Pharmaceuticals news, COO Ian F. Smith sold 75,000 shares of the stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $145.06, for a total transaction of $10,879,500.00. Following the transaction, the chief operating officer now directly owns 114,188 shares of the company’s stock, valued at $16,564,111.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Amit Sachdev sold 40,000 shares of the stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $145.05, for a total transaction of $5,802,000.00. Following the transaction, the executive vice president now directly owns 89,810 shares in the company, valued at $13,026,940.50. The disclosure for this sale can be found here. Insiders sold 192,491 shares of company stock worth $28,020,882 over the last ninety days. 1.80% of the stock is currently owned by company insiders.

Several research firms recently commented on VRTX. Royal Bank Of Canada reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Robert W. Baird reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. HC Wainwright reiterated a “hold” rating and issued a $85.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. Finally, Maxim Group reissued a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $173.15.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down $0.95 during midday trading on Monday, hitting $149.02. 203,455 shares of the stock were exchanged, compared to its average volume of 1,801,722. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. The firm has a market capitalization of $37,927.83, a P/E ratio of 249.95, a PEG ratio of 3.81 and a beta of 1.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same period in the prior year, the business posted $0.16 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 39.7% compared to the same quarter last year. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Stevens Capital Management LP Takes $12.44 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.watchlistnews.com/stevens-capital-management-lp-takes-12-44-million-position-in-vertex-pharmaceuticals-incorporated-vrtx/1682854.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.